Published in Cancer Biol Ther on February 03, 2009
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer (2010) 1.72
Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One (2012) 1.70
MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer (2010) 1.66
Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat (2010) 1.61
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta (2010) 1.58
Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol (2010) 1.51
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res (2010) 1.44
Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res (2010) 1.40
Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol (2011) 1.39
Cell-free Circulating miRNA Biomarkers in Cancer. J Cancer (2012) 1.37
Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology (2010) 1.31
MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One (2012) 1.27
MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res (2012) 1.24
Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology (2011) 1.22
Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer (2011) 1.20
MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci (2013) 1.18
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg (2012) 1.14
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One (2011) 1.12
Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One (2011) 1.09
Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer (2010) 1.06
Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist (2010) 1.06
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev (2010) 1.03
Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. Cancer Lett (2012) 1.02
Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol (2015) 1.01
miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett (2012) 1.01
MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett (2009) 1.01
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Transl Oncol (2014) 1.00
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.98
MicroRNAs in pancreatic malignancy: progress and promises. Cancer Lett (2014) 0.98
Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol (2014) 0.98
MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol (2012) 0.97
Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. Gut Liver (2015) 0.97
Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn (2011) 0.97
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer (2012) 0.95
Diagnostic value of microRNA for pancreatic cancer: a meta-analysis. Arch Med Sci (2012) 0.93
MicroRNAs in pancreatic ductal adenocarcinoma. World J Gastroenterol (2011) 0.93
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci (2013) 0.91
Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg (2011) 0.90
MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol (2013) 0.90
MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma. Diagn Pathol (2015) 0.88
Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg (2014) 0.88
New targeted therapies in pancreatic cancer. World J Gastroenterol (2015) 0.87
Tissue slide-based microRNA characterization of tumors: how detailed could diagnosis become for cancer medicine? Expert Rev Mol Diagn (2014) 0.87
Update on pancreatic cyst fluid analysis. Ann Gastroenterol (2013) 0.87
MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol (2016) 0.87
Regulating miRNA by natural agents as a new strategy for cancer treatment. Curr Drug Targets (2013) 0.87
Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin (2015) 0.86
Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterol (2014) 0.86
Endoscopic ultrasound and pancreatic cystic lesions-diagnostic and therapeutic applications. Endosc Ultrasound (2012) 0.85
MicroRNAs in stool samples as potential screening biomarkers for pancreatic ductal adenocarcinoma cancer. Am J Cancer Res (2014) 0.84
MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. Ann Surg Treat Res (2014) 0.84
Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis? Biomed Res Int (2016) 0.82
Pancreatic cystic lesions: How endoscopic ultrasound morphology and endoscopic ultrasound fine needle aspiration help unlock the diagnostic puzzle. World J Gastrointest Endosc (2012) 0.82
MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterol Res Pract (2015) 0.82
Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med (2014) 0.81
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas (2013) 0.81
Real-time monitoring of miRNA function in pancreatic cell lines using recombinant AAV-based miRNA Asensors. PLoS One (2013) 0.81
Intraductal papillary mucinous neoplasm of the pancreas: an update. Scientifica (Cairo) (2012) 0.81
MicroRNAs and cancer therapeutics. Pharm Res (2011) 0.81
Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des (2014) 0.81
Circulating MicroRNA-26a in Plasma and Its Potential Diagnostic Value in Gastric Cancer. PLoS One (2016) 0.81
The use of protein-based biomarkers for the diagnosis of cystic tumors of the pancreas. Int J Proteomics (2011) 0.80
The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis. Viruses (2015) 0.80
Noncoding RNAs and pancreatic cancer. World J Gastroenterol (2016) 0.79
Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncol (2016) 0.78
MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. Ann Surg (2017) 0.78
Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer. BMC Cancer (2015) 0.77
Appraising MicroRNA-155 as a Noninvasive Diagnostic Biomarker for Cancer Detection: A Meta-Analysis. Medicine (Baltimore) (2016) 0.77
Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol (2016) 0.77
Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. Respir Res (2009) 0.77
miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights (2015) 0.76
The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression. Int J Mol Sci (2016) 0.76
Prospects of miRNA-based therapy for pancreatic cancer. Curr Drug Targets (2013) 0.76
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget (2016) 0.76
Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Biomark Res (2017) 0.75
Computational Analysis of Specific MicroRNA Biomarkers for Noninvasive Early Cancer Detection. Biomed Res Int (2017) 0.75
Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol (2014) 0.75
Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data. Mol Med Rep (2016) 0.75
Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications. Int J Mol Sci (2016) 0.75
A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort. Mol Ther Nucleic Acids (2016) 0.75
Clinically relevant circulating microRNA profiling studies in pancreatic cancer using meta-analysis. Oncotarget (2017) 0.75
Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively. Biomed Res Int (2017) 0.75
Novel Biomarkers for Pancreatic Cysts. Dig Dis Sci (2017) 0.75
MicroRNA expression levels as diagnostic biomarkers for intraductal papillary mucinous neoplasm. Oncotarget (2017) 0.75
Diagnosis and Management of Pancreatic Cystic Neoplasms. Curr Treat Options Gastroenterol (2017) 0.75
Levels of MicroRNA Heterogeneity in Cancer Biology. Mol Diagn Ther (2017) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A (2005) 12.96
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
miRNAs, cancer, and stem cell division. Cell (2005) 12.15
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene (2007) 10.79
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
miRiad roles for the miR-17-92 cluster in development and disease. Cell (2008) 8.02
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology (2004) 6.75
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg (2003) 4.86
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer (2007) 4.59
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene (2007) 4.46
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A (2007) 4.04
microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet (2007) 3.63
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res (1976) 2.46
Precursors to invasive pancreatic cancer. Adv Anat Pathol (2005) 2.45
Endoscopic ultrasound-guided fine-needle aspiration. A cytopathologist's perspective. Am J Clin Pathol (2003) 2.25
Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer (2003) 2.24
Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an "intestinal" pathway of carcinogenesis in the pancreas. Am J Surg Pathol (2004) 1.96
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate (2008) 1.86
The role of pancreatic cyst fluid molecular analysis in predicting cyst pathology. Clin Gastroenterol Hepatol (2005) 1.78
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol (2002) 1.68
PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res (2006) 1.63
Cystic neoplasia of the pancreas: pathology and biology. J Gastrointest Surg (2007) 1.60
MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol (2004) 1.55
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol (2004) 1.40
Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg (2006) 1.36
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2002) 1.32
Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol (2004) 1.24
Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol (2003) 1.19
K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol (2006) 1.04
Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol (2005) 1.00
Incidental pancreatic cystic lesions. World J Surg (2008) 0.91
Tissue microdissection and processing. Cancer Treat Res (2001) 0.82
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
A hexanucleotide element directs microRNA nuclear import. Science (2007) 5.71
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A (2008) 5.15
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum (2012) 4.27
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet (2007) 3.63
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc (2008) 3.43
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology (2008) 2.71
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet (2004) 2.59
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut (2012) 2.52
Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol (2009) 2.51
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A (2010) 2.49
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res (2010) 2.39
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. Cancer Biol Ther (2008) 2.38
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res (2011) 1.97
Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis (2007) 1.94
LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev (2009) 1.93
Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res (2004) 1.93
Pancreatic cancer. Curr Probl Cancer (2002) 1.92